Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...
Gene therapy
YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...
SineuGene’s First-in-Class ALS Gene Therapy SNUG01 Gets NMPA Clinical Trial Clearance
Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders based in Beijing, announced that...
Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between...
Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China
Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has...
YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...
3SBio Partners with Thermo Fisher to Advance Cell and Gene Therapy Solutions
China-based 3SBio Inc. (HKG: 1530) announced last week a strategic partnership with US-based life sciences...
SineuGene’s ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation
Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced this week that...
Genevector’s JWK002 Gains NMPA IND Approval for XLRS Gene Therapy
China-based Chengdu Geneector Biotechnology Co., Ltd. (Genevector), a developer of AAV gene therapy drugs, announced...
Suzhou Porton Biologics Partners with Future Biotechnology to Expand Viral Vector Services
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a...
FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries
The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...
Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy
China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...
Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion
US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...
Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients
Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for...
YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101
Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...
StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment
Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...
AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...
Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss
South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...
Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...